Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24497826 | 1.00 | NR3C1 (0.38) | NR3C1TRPV6IDO1HCRTR2KDM4E | |
| SCHEMBL29487590 | 1.00 | NR3C1 (0.38) | NR3C1TRPV6IDO1HCRTR2KDM4E | |
| SCHEMBL22969642 | 1.00 | NR3C1 (0.38) | NR3C1TRPV6IDO1HCRTR2KDM4E | |
| SCHEMBL24497714 | 0.86 | OPRM1 (0.42) | KDM4EL3MBTL1 | |
| SCHEMBL24461039 | 0.85 | MAOB (0.42) | KDM4E | |
| SCHEMBL24461026 | 0.85 | MAOB (0.42) | KDM4E | |
| SCHEMBL23293093 | 0.85 | HCRTR2 (0.40) | HCRTR2 | |
| SCHEMBL29487560 | 0.85 | HCRTR2 (0.40) | HCRTR2 | |
| SCHEMBL23293095 | 0.85 | HCRTR2 (0.40) | HCRTR2 | |
| SCHEMBL28675350 | 0.85 | HCRTR2 (0.35) | IDO1HCRTR2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-4010314-B1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| CN-108884043-B | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2021-11-26 | — | — | CN | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | NR3C1 302/4885TRPV6 389/4885IDO1 1084/4885 |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | NR3C1 302/4885TRPV6 389/4885IDO1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.